PMID- 21645356
OWN - NLM
STAT- MEDLINE
DCOM- 20111010
LR  - 20211020
IS  - 1471-2172 (Electronic)
IS  - 1471-2172 (Linking)
VI  - 12
DP  - 2011 Jun 6
TI  - The interplay between surfaces and soluble factors define the immunologic and 
      angiogenic properties of myeloid dendritic cells.
PG  - 35
LID - 10.1186/1471-2172-12-35 [doi]
AB  - BACKGROUND: Dendritic cells (DCs) are antigen presenting cells capable of 
      inducing specific immune responses against microbial infections, transplant 
      antigens, or tumors. Interestingly, microenvironment conditions such as those 
      present in tumor settings might induce a DC phenotype that is poorly immunogenic 
      and with the capability of promoting angiogenesis. We hypothesize that this 
      plasticity may be caused not only by the action of specific cytokines or growth 
      factors but also by the properties of the surfaces with which they interact, such 
      as extracellular matrix (ECM) components. RESULTS: Herewith we studied the effect 
      of different surfaces and soluble factors on the biology of DCs. To accomplish 
      this, we cultured murine myeloid(m) DCs on surfaces coated with fibronectin, 
      collagen I, gelatin, and Matrigel using poly-D-lysine and polystyrene as 
      non-biological surfaces. Further, we cultured these cells in the presence of 
      regular DC medium (RPMI 10% FBS) or commercially available endothelial medium 
      (EGM-2). We determined that mDCs could be kept in culture up to 3 weeks in these 
      conditions, but only in the presence of GM-CSF. We were able to determine that 
      long-term DC cultures produce an array of angiogenic factors, and that some of 
      these cultures still retain the capability to induce T cell responses. 
      CONCLUSIONS: Altogether these data indicate that in order to design DC-based 
      vaccines or treatments focused on changing the phenotype of DCs associated with 
      diseases such as cancer or atherosclerosis, it becomes necessary to fully 
      investigate the microenvironment in which these cells are present or will be 
      delivered.
FAU - Sprague, Leslee
AU  - Sprague L
AD  - Biomedical Engineering Program, Russ College of Engineering and Technology, Ohio 
      University, USA.
FAU - Muccioli, Maria
AU  - Muccioli M
FAU - Pate, Michelle
AU  - Pate M
FAU - Meles, Evan
AU  - Meles E
FAU - McGinty, John
AU  - McGinty J
FAU - Nandigam, Harika
AU  - Nandigam H
FAU - Venkatesh, Amritha K
AU  - Venkatesh AK
FAU - Gu, Ming-Yu
AU  - Gu MY
FAU - Mansfield, Kristen
AU  - Mansfield K
FAU - Rutowski, Andrew
AU  - Rutowski A
FAU - Omosebi, Omowaleola
AU  - Omosebi O
FAU - Courreges, Maria C
AU  - Courreges MC
FAU - Benencia, Fabian
AU  - Benencia F
LA  - eng
GR  - R15 CA137499-01/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20110606
PL  - England
TA  - BMC Immunol
JT  - BMC immunology
JID - 100966980
RN  - 0 (Angiogenic Proteins)
RN  - 0 (Collagen Type I)
RN  - 0 (Drug Combinations)
RN  - 0 (Fibronectins)
RN  - 0 (Laminin)
RN  - 0 (Polystyrenes)
RN  - 0 (Proteoglycans)
RN  - 119978-18-6 (matrigel)
RN  - 25104-18-1 (Polylysine)
RN  - 9000-70-8 (Gelatin)
RN  - 9007-34-5 (Collagen)
SB  - IM
MH  - Angiogenic Proteins/metabolism
MH  - Animals
MH  - Cell Culture Techniques/methods
MH  - Cell Line, Tumor
MH  - Collagen
MH  - Collagen Type I/pharmacology
MH  - Dendritic Cells/drug effects/*physiology
MH  - Drug Combinations
MH  - Female
MH  - Fibronectins/pharmacology
MH  - Gelatin/pharmacology
MH  - Laminin
MH  - Lymphocyte Activation/drug effects
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Myeloid Cells/drug effects/*physiology
MH  - Polylysine
MH  - Polystyrenes
MH  - Proteoglycans
MH  - T-Lymphocytes/immunology
PMC - PMC3124423
EDAT- 2011/06/08 06:00
MHDA- 2011/10/11 06:00
PMCR- 2011/06/06
CRDT- 2011/06/08 06:00
PHST- 2010/10/23 00:00 [received]
PHST- 2011/06/06 00:00 [accepted]
PHST- 2011/06/08 06:00 [entrez]
PHST- 2011/06/08 06:00 [pubmed]
PHST- 2011/10/11 06:00 [medline]
PHST- 2011/06/06 00:00 [pmc-release]
AID - 1471-2172-12-35 [pii]
AID - 10.1186/1471-2172-12-35 [doi]
PST - epublish
SO  - BMC Immunol. 2011 Jun 6;12:35. doi: 10.1186/1471-2172-12-35.